RE: Sales3 Mar 2024 12:04
I have no doubts that this is going to be a very popular product, whether one suffers from diagnosed ED, or not.
Apart from the ED market, There are numerous occasions whereby perfectly young & healthy men have erection issues, stress, overtired, ‘stage fright’ with a new partner, too much alcohol etc etc.
Having some gel handy, aswell as a condom or 2, will become the norm.
In regards to the reviews, The NHS has approved the product for prescription, so it has already undergone strict approval processes proving its effectiveness.
My interest at this stage is how much FUM is going to be worth within 6, 12, 18 months time?
If annual sales accelerate and Eroxon takes a minimum of 20% of the Global market (£4.7Bn) then consider our MCap then.
Personally, being able to buy OTC & use a product like Eroxon, that works within 10 minutes, without side effects, will Trump products that take an hour, such as Viagra, with a number of well documented side effects, plus an interview before one can purchase it.
So, I consider our market will gain increasing traction and eventual sales will be phenomenal.